Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ajmaline Provocation in Healthy Subjects
NCT02933437Phase 2Unknown
- Sponsor
- St George's, University of London
- Start
- Oct 2017
- Primary completion
- Dec 2019
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ajmaline in Brugada syndrome, sponsored by St George's, University of London. Primary endpoint: Qualitative and quantitative effects of ajmaline provocation on parameters of cardiac conduction at 10 minutes. Status: unknown.
02
Drugs
ajmaline
03
Conditions
Brugada syndrome
Beyond the preview
Go deeper on NCT02933437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02933437.